Unknown

Dataset Information

0

Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomised, multicentre, double blind, placebo controlled GO-FURTHER trial.


ABSTRACT:

Objective

Report on radiographic effects and maintenance of clinical benefit with intravenous golimumab 2 mg/kg+methotrexate (MTX) for up to week (wk) 52 in active rheumatoid arthritis (RA).

Methods

Patients (n=592) with active RA (?6/66 swollen, ?6/68 tender joints, C reactive protein (CRP) ?1.0 mg/dL and positive for rheumatoid factor and/or anticyclic citrullinated protein antibody at screening) despite MTX ?3 months (stable dose of 15-25 mg/week for ?4 weeks) participated in this multicentre, international, randomised, double blind, placebo controlled, phase 3 study. Patients were randomised (2:1) to receive intravenous golimumab 2 mg/kg or placebo infusions at weeks 0 and 4 and then every 8 weeks; patients continued their stable MTX regimen. Placebo patients started golimumab 2 mg/kg at wk16 (early escape; <10% improvement in tender and swollen joints) or wk24 (crossover by design). Week 24 and wk52 radiographic (van der Heijde-Sharp (vdH-S) scores), clinical efficacy and safety data up to 1 year are reported here.

Results

Significant and rapid clinical improvement was observed up to wk24 of intravenous golimumab therapy. Golimumab+MTX treated patients demonstrated less radiographic progression than placebo treated patients at wk24 (vdH-S score mean change 0.03 vs 1.09; p<0.001) and wk52 (0.13 vs 1.22; p=0.001). Among patients with ?20% improvement in the American College of Rheumatology response criteria or who achieved a 'good' or 'moderate' response according to the 28 joint Disease Activity Score employing CRP at wk24, approximately 80% maintained this response up until wk52. Through an average of 43.5 weeks of follow-up, 64.6% of patients receiving golimumab+MTX reported adverse events, most commonly non-serious infections.

Conclusions

In patients with active RA despite MTX, intravenous golimumab+MTX yielded significant inhibition of structural damage at wk24 and wk52, and sustained clinical improvement in signs and symptoms with no new safety signals up to 1 year.

Clinicaltrialsgov

NCT00973479, EudraCT 2008-006 064-11.

SUBMITTER: Weinblatt ME 

PROVIDER: S-EPMC4251163 | biostudies-literature | 2014 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomised, multicentre, double blind, placebo controlled GO-FURTHER trial.

Weinblatt Michael E ME   Westhovens Rene R   Mendelsohn Alan M AM   Kim Lilianne L   Lo Kim Hung KH   Sheng Shihong S   Noonan Lenore L   Lu Jiandong J   Xu Zhenhua Z   Leu Jocelyn J   Baker Daniel D   Bingham Clifton O CO  

Annals of the rheumatic diseases 20130903 12


<h4>Objective</h4>Report on radiographic effects and maintenance of clinical benefit with intravenous golimumab 2 mg/kg+methotrexate (MTX) for up to week (wk) 52 in active rheumatoid arthritis (RA).<h4>Methods</h4>Patients (n=592) with active RA (≥6/66 swollen, ≥6/68 tender joints, C reactive protein (CRP) ≥1.0 mg/dL and positive for rheumatoid factor and/or anticyclic citrullinated protein antibody at screening) despite MTX ≥3 months (stable dose of 15-25 mg/week for ≥4 weeks) participated in t  ...[more]

Similar Datasets

| S-EPMC4924564 | biostudies-literature
| S-EPMC5063174 | biostudies-literature
| S-EPMC3046519 | biostudies-literature
| S-EPMC3372319 | biostudies-literature
| S-EPMC4613151 | biostudies-literature
| S-EPMC4173740 | biostudies-literature
| S-EPMC4755132 | biostudies-literature
| S-EPMC6701065 | biostudies-literature
| S-EPMC7497341 | biostudies-literature
| S-EPMC5765449 | biostudies-literature